Raymond James Financial
FATE icon

Raymond James Financial’s Fate Therapeutics FATE Stock Holding History

Raymond James Financial’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,450
Closed -$1.62K – 5550
2025
Q2 		$1.62K Buy
+1,450
New +$1.69K ﹤0.01% 6460

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wilshire Advisors Santa Monica, California $10.3M AUM 79.91% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Raymond James Financial's FATE Position: Q3 2025 in Review

Raymond James Financial sold out of Fate Therapeutics (FATE) in Q3 2025, closing a stake of 1,450 shares — an estimated $1.62K sold.

Raymond James Financial first reported a position in FATE in Q2 2025 and held it in 1 quarter. The position peaked at $1.62K in Q2 2025. 143 funds tracked by Wall St. Rank hold FATE as of Q3 2025.

  • Raymond James Financial reported no remaining Fate Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 1,450 Fate Therapeutics shares in Q3 2025, an estimated $1.62K.
  • Raymond James Financial first reported a position in Fate Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Fate Therapeutics position peaked at $1.62K in Q2 2025.
  • 143 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.